bpc-157 chemical structure BPC-157: Mechanism, Sequence & Identity

Phase 2 cagrilintide alone ~10.8% body weight reduction at 26 weeks (4.5mg) Phase 2 CagriSema combo ~15.6% body weight reduction at 32 weeks Phase 3 REDEFINE 1 ~22.7% body weight reduction at 68 weeks Phase 2 CagriSema combination trial The Phase 2 trial of CagriSema was published in The Lancet in 2023, and its results attracted immediate attention

More study results are expected in 2026, and it could potentially be approved as early as 2027

TB-500 has a longer plasma half-life of approximately 2-3 hours due to its larger molecular size (~4963 g/mol) and slower clearance

I purchased this after originally purchasing B12

Adenosylcobalamin Injections: Adenosylcobalamin is less commonly available as an injection but may require similar storage conditions to other B12 formulations